Antibiotics and BCG

Affiliations

Edward M Messing. Bladder Cancer. 2022.

. 2022 Mar 11;8(1):97-99.

doi: 10.3233/BLC-229000. eCollection 2022.

No abstract available

Conflict of interest statement

The author has no conflicts of interest to report.

1. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–3. doi: 10.1016/s0022-5347(17)58737-6. PMID: 820877. - DOI - PubMed
1. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA Jr, Sullivan J, Sarosdy MF, et al.. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325(17):1205–9. doi: 10.1056/NEJM199110243251703. PMID: 1922207. - DOI - PubMed
1. Kamat AM, Flaig TW, Grossman HB, et al.. Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. 2015;12(4):225–35. doi: 10.1038/nrurol.2015.58. - DOI - PubMed
1. Alexandroff AB, Jackson AM, O’Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 1999;353(9165):353–94. doi: 10.1016/S0140-6736(98)07422-4. - DOI - PubMed
1. Shang Z, Li Y, Zhang M, et al.. Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression. Mol Cancer Ther. 2015;14(11):2586–94. doi: 10.1158/1535-7163.MCT-14-1055-T. - DOI - PMC - PubMed